Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
41 participants
INTERVENTIONAL
2009-10-29
2013-02-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)
NCT02574260
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
NCT03002376
Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
NCT02297529
ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
NCT00656305
Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer
NCT06670300
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anti-NGF AB
Anti-NGF AB
Solution for injection, 10 mg, one injection/8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-NGF AB
Solution for injection, 10 mg, one injection/8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Karnofsky Performance Score ≥40% at Baseline;
* patients randomized and treated with intravenous study drug in double-blind Study A4091003.
Exclusion Criteria
* Occurrence of any adverse event or condition during Study A4091003 or since termination from that study that, in the opinion of the Investigator, would put the patient at increased safety risk or should exclude the subject from participating in the open-label extension Study A4091029.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSD Center for Pain Medicine
La Jolla, California, United States
UCSD Medical Center - Thornton Hospital
La Jolla, California, United States
UCSD Periman Ambulatory Care Center
La Jolla, California, United States
UCSD Moores Cancer Center
La Jolla, California, United States
WK River Cities Clinical Research Center
Shreveport, Louisiana, United States
Huntsman Cancer Institute
Salt Lake City, Utah, United States
Nuhr Zentrum
Senftenberg, , Austria
Clinic of Oncology
Banja Luka, , Bosnia and Herzegovina
General Hospital Varazdin
Varaždin, , Croatia
Fejer Megyei Szt. Gyorgy Korhaz - Rendelointezet/Aneszteziologiai es Intenziv Betegellato Osztaly
Székesfehérvár, , Hungary
Central India Cancer Research Institute Central India Cancer Research Institute
Nagpur, Maharashtra, India
Shatabdi Super Speciality Hospital
Nashik, Maharashtra, India
Chhatrapati Shahuji Maharaj Medical University
Lucknow, Uttar Pradesh, India
Latvian Oncology Centre
Riga, , Latvia
Niepubliczny Zaklad Opieki Zdrowotnej
Bydgoszcz, , Poland
Hospicjum im Ks Eugeniusza Dutkiewicza SAC w Gdansku
Gdansk, , Poland
**Poradnia Medycyny Paliatywnej, Hospicjum Palium
Poznan, , Poland
Wielkopolskie Centrum Onkologii im. Marii Sklodowskiej-Curie
Poznan, , Poland
NZOZ Zespol Opieki Domowej Polskiego Towarzystwa Opieki Paliatywnej
Włocławek, , Poland
Fakultna Nemocina s Poliklinikou FD Roosevelta Banska Bystrica
Banská Bystrica, , Slovakia
Narodny onkologicky ustav
Bratislava, , Slovakia
Severance Hospital, Yonsei University College of Medicine
Seodaemun-gu, Seoul, South Korea
Samsung Medical Center, Division of Hematology-Oncology, Department of Medicine
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sopata M, Katz N, Carey W, Smith MD, Keller D, Verburg KM, West CR, Wolfram G, Brown MT. Efficacy and safety of tanezumab in the treatment of pain from bone metastases. Pain. 2015 Sep;156(9):1703-1713. doi: 10.1097/j.pain.0000000000000211.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-005182-66
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CANCER PAIN OL EXTENSION
Identifier Type: OTHER
Identifier Source: secondary_id
A4091029
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.